whitepaper
Article: Understanding potency in cell and gene therapy development
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
List view / Grid view
Proteomics
whitepaper
Article: Challenges in developing CAR T-cell therapies
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
whitepaper
Whitepaper: Correlate protein expression with genomic data and IHC
Measure protein, DNA and RNA in FFPE tissue samples using rigorously IHC validated CST antibodies on the NanoString® nCounter® platform.
news
The future of drug development: AI tailors artificial DNA
Swedish researchers have designed synthetic DNA that controls a cells’ protein production using AI.
video
Video: Proteomics solutions for drug discovery
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.
whitepaper
Whitepaper: Unique solutions for drug discovery and development
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
news
Novel synthetic peptides could suppress formation of harmful amyloid aggregates
German researchers have designed peptides that bind to amyloidogenic proteins linked to Alzheimer’s and type 2 diabetes, to effectively suppress both cytotoxic amyloid aggregation and amyloid cross-accelerating interactions.
whitepaper
Product hub: Targeted protein degradation – next-generation therapeutics
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
article
Synthetic biology is ready for the therapeutic limelight
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
article
T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
article
Drug Target Review Antibodies ebook 2022
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
article
Drug Target Review – Issue 3 2022
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
whitepaper
Application note: Hyperion+ imaging system
A powerful tool to study complex phenotypes and cellular interactions. Map spatial interactions twice as fast with this second-generation system.
whitepaper
ebook: LC-MS analysis for (bio)pharmaceutical research
Are you using LC-MS in your drug development studies and looking to automate your sample prep workflow? Download our ebook to learn more.
webinar
Decoding cancer and inflammation: identifying selective inhibitors of SH2 domains
31 August 2022 | By Eurofins Discovery
Watch our on-demand webinar where our expert speaker will explore the possibilities for designing selective small molecules targeting the SH2 domains of STAT proteins plus more.